Biocon Limited
Biocon Limited, together with its subsidiaries, manufactures and sells biotechnology products and research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics, Biosimilars, and Research segments. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, multiple sclerosis, a… Read more
Biocon Limited (BIOCON) - Net Assets
Latest net assets as of December 2025: ₹340.14 Billion INR
Based on the latest financial reports, Biocon Limited (BIOCON) has net assets worth ₹340.14 Billion INR as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹635.54 Billion) and total liabilities (₹295.40 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹340.14 Billion |
| % of Total Assets | 53.52% |
| Annual Growth Rate | 20.39% |
| 5-Year Change | 225.74% |
| 10-Year Change | 534.62% |
| Growth Volatility | 26.93 |
Biocon Limited - Net Assets Trend (2004–2025)
This chart illustrates how Biocon Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Biocon Limited (2004–2025)
The table below shows the annual net assets of Biocon Limited from 2004 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹277.12 Billion | +9.64% |
| 2024-03-31 | ₹252.75 Billion | +12.39% |
| 2023-03-31 | ₹224.89 Billion | +137.47% |
| 2022-03-31 | ₹94.70 Billion | +11.31% |
| 2021-03-31 | ₹85.08 Billion | +15.23% |
| 2020-03-31 | ₹73.83 Billion | +10.08% |
| 2019-03-31 | ₹67.07 Billion | +18.74% |
| 2018-03-31 | ₹56.48 Billion | +8.34% |
| 2017-03-31 | ₹52.14 Billion | +19.40% |
| 2016-03-31 | ₹43.67 Billion | +26.84% |
| 2015-03-31 | ₹34.43 Billion | +10.74% |
| 2014-03-31 | ₹31.09 Billion | +12.65% |
| 2013-03-31 | ₹27.60 Billion | +21.25% |
| 2012-03-31 | ₹22.76 Billion | +9.93% |
| 2011-03-31 | ₹20.71 Billion | +15.57% |
| 2010-03-31 | ₹17.92 Billion | +16.68% |
| 2009-03-31 | ₹15.36 Billion | +3.97% |
| 2008-03-31 | ₹14.77 Billion | +38.30% |
| 2007-03-31 | ₹10.68 Billion | +19.80% |
| 2006-03-31 | ₹8.91 Billion | +20.22% |
| 2005-03-31 | ₹7.41 Billion | +31.70% |
| 2004-03-31 | ₹5.63 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Biocon Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3595.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹189.59 Billion | 87.60% |
| Common Stock | ₹6.00 Billion | 2.77% |
| Other Comprehensive Income | ₹19.05 Billion | 8.80% |
| Other Components | ₹1.80 Billion | 0.83% |
| Total Equity | ₹216.44 Billion | 100.00% |
Biocon Limited Competitors by Market Cap
The table below lists competitors of Biocon Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
China Nuclear Engineering Co
SHG:601611
|
$2.54 Billion |
|
Steel Authority of India Limited
NSE:SAIL
|
$2.54 Billion |
|
Beijing Ultrapower Software
SHE:300002
|
$2.54 Billion |
|
Firefly Aerospace Inc. Common Stock
NASDAQ:FLY
|
$2.55 Billion |
|
THE VITA COCO CO.INC.-01
F:85E
|
$2.54 Billion |
|
Mankind Pharma Ltd
NSE:MANKIND
|
$2.54 Billion |
|
Stella-Jones Inc
PINK:STLJF
|
$2.54 Billion |
|
China Zhenhua Group Science & Technology Co Ltd
SHE:000733
|
$2.54 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Biocon Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 197,837,000,000 to 216,440,000,000, a change of 18,603,000,000 (9.4%).
- Net income of 10,133,000,000 contributed positively to equity growth.
- Dividend payments of 829,000,000 reduced retained earnings.
- Share repurchases of 104,000,000 reduced equity.
- New share issuances of 104,000,000 increased equity.
- Other comprehensive income increased equity by 4,557,000,000.
- Other factors increased equity by 4,742,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹10.13 Billion | +4.68% |
| Dividends Paid | ₹829.00 Million | -0.38% |
| Share Repurchases | ₹104.00 Million | -0.05% |
| Share Issuances | ₹104.00 Million | +0.05% |
| Other Comprehensive Income | ₹4.56 Billion | +2.11% |
| Other Changes | ₹4.74 Billion | +2.19% |
| Total Change | ₹- | 9.40% |
Book Value vs Market Value Analysis
This analysis compares Biocon Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.09x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 69.98x to 2.09x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-03-31 | ₹5.40 | ₹377.55 | x |
| 2005-03-31 | ₹6.37 | ₹377.55 | x |
| 2006-03-31 | ₹7.65 | ₹377.55 | x |
| 2007-03-31 | ₹9.17 | ₹377.55 | x |
| 2008-03-31 | ₹12.42 | ₹377.55 | x |
| 2009-03-31 | ₹12.69 | ₹377.55 | x |
| 2010-03-31 | ₹14.82 | ₹377.55 | x |
| 2011-03-31 | ₹17.17 | ₹377.55 | x |
| 2012-03-31 | ₹19.14 | ₹377.55 | x |
| 2013-03-31 | ₹22.73 | ₹377.55 | x |
| 2014-03-31 | ₹25.42 | ₹377.55 | x |
| 2015-03-31 | ₹27.26 | ₹377.55 | x |
| 2016-03-31 | ₹34.40 | ₹377.55 | x |
| 2017-03-31 | ₹40.79 | ₹377.55 | x |
| 2018-03-31 | ₹43.62 | ₹377.55 | x |
| 2019-03-31 | ₹51.20 | ₹377.55 | x |
| 2020-03-31 | ₹56.48 | ₹377.55 | x |
| 2021-03-31 | ₹63.73 | ₹377.55 | x |
| 2022-03-31 | ₹70.49 | ₹377.55 | x |
| 2023-03-31 | ₹149.40 | ₹377.55 | x |
| 2024-03-31 | ₹165.30 | ₹377.55 | x |
| 2025-03-31 | ₹180.70 | ₹377.55 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Biocon Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.68%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.64%
- • Asset Turnover: 0.26x
- • Equity Multiplier: 2.72x
- Recent ROE (4.68%) is below the historical average (14.65%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 24.63% | 27.62% | 0.64x | 1.40x | ₹823.43 Million |
| 2005 | 26.68% | 30.56% | 0.59x | 1.47x | ₹1.23 Billion |
| 2006 | 19.59% | 25.30% | 0.53x | 1.45x | ₹851.42 Million |
| 2007 | 18.74% | 24.34% | 0.52x | 1.47x | ₹934.01 Million |
| 2008 | 31.26% | 55.66% | 0.40x | 1.40x | ₹3.15 Billion |
| 2009 | 6.16% | 6.79% | 0.54x | 1.68x | ₹-579.53 Million |
| 2010 | 16.68% | 14.40% | 0.69x | 1.67x | ₹1.17 Billion |
| 2011 | 18.08% | 15.98% | 0.65x | 1.75x | ₹1.64 Billion |
| 2012 | 14.89% | 16.52% | 0.52x | 1.74x | ₹1.11 Billion |
| 2013 | 18.89% | 20.48% | 0.56x | 1.64x | ₹2.39 Billion |
| 2014 | 13.67% | 13.39% | 0.54x | 1.90x | ₹1.11 Billion |
| 2015 | 15.21% | 16.10% | 0.48x | 1.95x | ₹1.70 Billion |
| 2016 | 22.10% | 26.77% | 0.39x | 2.09x | ₹4.91 Billion |
| 2017 | 12.65% | 15.73% | 0.41x | 1.94x | ₹1.28 Billion |
| 2018 | 7.19% | 9.03% | 0.41x | 1.93x | ₹-1.46 Billion |
| 2019 | 14.85% | 16.42% | 0.45x | 2.00x | ₹2.96 Billion |
| 2020 | 11.16% | 11.88% | 0.44x | 2.15x | ₹776.20 Million |
| 2021 | 9.71% | 10.37% | 0.39x | 2.43x | ₹-221.90 Million |
| 2022 | 7.69% | 7.92% | 0.40x | 2.42x | ₹-1.95 Billion |
| 2023 | 2.59% | 4.14% | 0.21x | 2.91x | ₹-13.24 Billion |
| 2024 | 5.17% | 6.93% | 0.26x | 2.83x | ₹-9.56 Billion |
| 2025 | 4.68% | 6.64% | 0.26x | 2.72x | ₹-11.51 Billion |
Industry Comparison
This section compares Biocon Limited's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $14,687,312,434
- Average return on equity (ROE) among peers: -10.41%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Biocon Limited (BIOCON) | ₹340.14 Billion | 24.63% | 0.87x | $2.54 Billion |
| Anthem Biosciences Ltd (ANTHEM) | $17.41 Billion | 22.13% | 0.16x | $17.29 Million |
| BALAXI PHARMACEUTICALS LIMITED (BALAXI) | $15.55 Million | -49.65% | 0.08x | $10.46 Million |
| Blue Jet Healthcare Limited (BLUEJET) | $8.45 Billion | 19.37% | 0.25x | $134.93 Million |
| Concord Biotech Limited (CONCORDBIO) | $18.13 Billion | 20.50% | 0.12x | $346.78 Million |
| Dishman Carbogen Amcis Limited (DCAL) | $9.29 Billion | 6.11% | 1.42x | $103.76 Million |
| Haleos Labs Limited (HALEOSLABS) | $1.06 Billion | 16.78% | 1.56x | $129.20K |
| Lyka Labs Limited (LYKALABS) | $582.36 Million | -29.66% | 3.04x | $8.51 Million |
| ONESOURCE SPECIALTY PHARMA LTD (ONESOURCE) | $75.29 Billion | 0.00% | 0.00x | $1.21 Billion |
| Panacea Biotec Limited (PANACEABIO) | $1.96 Billion | -99.24% | 6.10x | $56.46 Million |